Welcome to our dedicated page for Zymeworks news (Ticker: ZYME), a resource for investors and traders seeking the latest updates and insights on Zymeworks stock.
Zymeworks Inc. (Nasdaq: ZYME) generates frequent news flow as a biotechnology and clinical-stage biopharmaceutical company managing licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics. Company announcements highlight its focus on difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, and its integrated model that combines internal R&D with an asset and royalty aggregation strategy.
News about Zymeworks often centers on clinical trial progress and key data readouts. A major theme is the development of Ziihera ® (zanidatamab-hrii), a HER2-targeted bispecific antibody engineered using the company’s Azymetric™ technology. Press releases have detailed positive Phase 3 HERIZON-GEA-01 results in first-line HER2-positive gastroesophageal adenocarcinoma, as well as regulatory approvals for previously treated HER2-positive biliary tract cancer in the U.S., Europe, and China. Updates also cover the advancement of partnered programs like pasritamig with Johnson & Johnson Innovative Medicine and early-stage data from wholly owned ADC candidates such as ZW191 and ZW251.
Investors following ZYME news can also expect regular coverage of strategic and corporate developments. The company reports on its evolving royalty- and asset-focused strategy, share repurchase authorizations, milestone and royalty revenues from partners, and leadership and board appointments designed to support capital allocation and partnership execution. Participation in major medical and investor conferences, such as ASCO GI and the J.P. Morgan Healthcare Conference, is another recurring topic in its news releases.
This news feed provides a centralized view of Zymeworks’ clinical milestones, partnership updates, financial and strategic announcements, and governance changes, offering context for how the company is executing its stated goal of building a diversified portfolio of revenue-generating healthcare assets alongside an active R&D engine.
Zymeworks Inc. (NYSE: ZYME) has completed enrollment in its pivotal HERIZON-BTC-01 clinical trial, assessing the antitumor efficacy of zanidatamab for patients with advanced HER2-amplified biliary tract cancers. Results are anticipated in early 2023. This trial addresses a significant need, as over 210,000 new cases of biliary tract cancers are diagnosed globally each year, with limited treatment options available. Zanidatamab has received Breakthrough Therapy designation from the FDA for this indication, highlighting its potential to improve patient outcomes.
Zymeworks Inc. (NYSE: ZYME) announced the acceptance of two abstracts for poster presentations at the 2022 ASCO Annual Meeting, scheduled for June 3-7, 2022. The first poster will showcase Phase 1b/2 data of zanidatamab combined with CAPOX chemotherapy and tislelizumab for HER2-positive advanced gastric cancer on June 4. The second presentation, on June 6, will feature preliminary data of zanidatamab with docetaxel for advanced HER2-positive breast cancer. Both presentations will be accessible on the Zymeworks website.
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company, will announce its Q1 2022 financial results on May 4, 2022, after market close. A conference call and webcast to discuss the results will follow at 4:30 p.m. ET. Investors can join the call by dialing 844-435-7258 (U.S. & Canada) or +1-631-485-4286 (international). Zymeworks is known for its innovative biotherapeutics, including its lead candidate, zanidatamab, a HER2-targeted bispecific antibody currently in clinical trials.
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical firm, announced its participation in two key investor conferences. On April 12, the company will hold one-on-one meetings at the Wells Fargo 2022 Biotech Forum in Palm Beach Gardens, FL. Additionally, Zymeworks will present and participate in meetings on May 2 at Bloom Burton & Co. Healthcare Investor Conference at 2:00 p.m. ET. These events will be webcast live, providing further engagement opportunities for investors.
Zymeworks Inc. (NYSE: ZYME) announced participation in two upcoming investor conferences in March 2022. The company will present at the Barclays Global Healthcare Conference on March 16 at 8:00 a.m. ET in Miami, FL, and a virtual fireside chat at Citi’s 2022 Winter Biotech Virtual Bus Tour on March 23 at 2:45 p.m. ET. Both events will be available via live webcast on Zymeworks’ website. Zymeworks is focused on developing next-generation biotherapeutics, including its lead candidate, zanidatamab, for treating solid tumors expressing HER2.
Zymeworks Inc. (NYSE: ZYME) reports pivotal trial progress for zanidatamab in gastroesophageal adenocarcinoma and biliary tract cancer, with expected enrollment completion dates in 2023 and mid-2022, respectively. The company's financial position is enhanced by a successful equity offering in January 2022, extending its cash runway into the second half of 2023. A workforce reduction exceeding 25% is in progress, alongside the appointment of Chris Astle, PhD, as CFO. Zymeworks expects to provide significant data updates in 2022 and continues to focus on partnerships to strengthen its financial position.
Zymeworks Inc. (NYSE: ZYME) has announced it will report its fourth quarter and full year 2021 financial results after market close on February 24, 2022. A conference call and webcast to discuss the results will take place on the same day at 4:30 p.m. ET. Zymeworks is a clinical-stage biopharmaceutical company focused on developing multifunctional biotherapeutics, including its lead candidate, zanidatamab, which targets HER2 in solid tumors. The firm also has a preclinical pipeline and is engaged in strategic partnerships to advance its therapies.
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company, will participate in two upcoming investor conferences. Management will engage in one-on-one meetings and fireside chats at the Guggenheim Oncology Conference on February 9, 2022, at 1:00 p.m. ET, and at the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022, at 3:40 p.m. ET. Both sessions will be webcast live and available for replay. Zymeworks focuses on developing multifunctional biotherapeutics, including its lead candidate, zanidatamab.
Zymeworks Inc. (NYSE: ZYME) has successfully closed a public offering of 11,035,000 common shares, which includes the exercise of an underwriters’ option for an additional 1,875,000 shares. The shares were priced at
Zymeworks Inc. (NYSE: ZYME) announced the pricing of its public offering, which includes 9,160,000 common shares and up to 3,340,000 pre-funded warrants. The shares are priced at $8.00 each, while the warrants are at $7.9999, totaling approximately $100 million in gross proceeds. A 30-day option for underwriters to purchase an additional 1,875,000 common shares is also available. The offering is set to close on or around January 31, 2022, subject to customary conditions.
FAQ
What is the current stock price of Zymeworks (ZYME)?
What is the market cap of Zymeworks (ZYME)?
